• Francisco Velasco, José D Carrillo-Ruiz, Víctor Salcido, Guillermo Castro, Julián Soto, and Ana Luisa Velasco.
• Unit for Stereotactic and Functional Neurosurgery and Radiosurgery, Mexico General Hospital, Mexico, D.F., Mexico.
• Neuromodulation. 2016 Jun 1; 19 (4): 357-64.

BackgroundPrelemniscal radiations (Raprl) have been proposed as a target for the treatment of Parkinson's disease. We evaluated effectiveness of this target through UPDRS-III in patients treated with Raprl deep brain stimulation (Raprl-DBS) and followed from 24 to 48 months.MethodsNineteen patients in Hoehn-Yahr stages II-III were implanted with tetrapolar deep brain stimulation electrodes in Raprl contralateral to the extremities with more prominent symptoms. Placement was assisted by MRI/CT/anatomical atlas fusion, microelectrode recording, and micro- and macro-stimulation. The effect on motor symptoms was evaluated in an open label protocol through specific items of the UPDRS-III score, applied pre-operatively and 6, 12, 24, and 48 months after the onset of stimulation in an OFF-medication/ON-stimulation condition. Changes in scores with regard to pre-operative condition were obtained for each symptom in both sides and statistical significance determined through double-tail Wilcoxon test. Influence of demographic variables on outcome was analyzed using linear regression testing.ResultsA greater than 80% decrease in UPDRS score for contralateral symptoms (classified as excellent results) occurred in 14 patients (73.7%), while in the other 5 it decreased from 33 to 79% (considered suboptimal results). These changes remained statistically significant up to 48 months (p < 0.01), while ipsilateral symptoms progressively increased. Suboptimal results were associated with selective improvement of only one symptom.ConclusionRaprl-DBS induces a long-term, significant improvement of contralateral acral symptoms of Parkinson's disease.© 2016 International Neuromodulation Society.

27 keywords...

hide…